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Abstract 
Increased of estrogen receptor (ER) expression resulting in activation of downstream signaling pathways 
including cAMP/PKA, MAPK/ERK and PI3K/AKT. The Association of estrogen receptor expression and P-
glycoprotein 1 (P-gp) expression is not clear yet. The aims of this study is to explore the influence of signaling 
cascades of estrogen receptors  and P-gp expression. This is an observational study with cross sectional design. 
Total 55 samples of invasive ductal carcinoma acquired for Immunohistochemistry examination. Analysis of ER 
and P-gp using chi square. This study found proportion  of  ER expression  were  35/ 55 (63.6 %), and P-gp 
expression were 10/55 (18.2%) in invasive ductal carcinoma of breast cancer.  Co-expression of  ER and P-gp  
expression were 17.1%.  There was no significant association between expression of  ER and P-gp with p 
value=0.076 (p>0.05), OR(95%CI) 1.2(0.21-5.99).  This results suggest that ER does not play a signiﬁcant role 
in the expression of P-gp in breast cancer.  
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1. Introduction  
The main problem in the treatment of breast cancer is the development of resistance to various chemotherapy 
Agents.  P-glycoprotein 1 (permeability glycoprotein, abbreviated as P-gp or Pgp) also known as multidrug 
resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) or cluster of 
differentiation 243 (CD243) is an important protein of the cell membrane that pumps many foreign substances 
out of cells. More formally, it is an ATP-dependent efflux pump with broad substrate specificity. Although the 
role of multidrug resistance 1 (MDR1) gene in inducing drug resistance in cancer has been studied clinically but 
expression in breast cancer is unclear [1]. Mechanisms of chemotherapy resistance can occur intrinsically or 
acquired through multiple mechanisms [2]. Resistance to chemotherapy in breast cancer is involving of estrogen 
receptor (ER) expression and permeability glycoprotein (P-gp), causing the efflux of various chemotherapeutic 
agents [3]. Research on the contribution of ER in resistance to chemotherapy  involving P-gp or MDR1 is still 
controversy [4,5]. The aims of this study is to explore the influence of signaling cascades of estrogen receptors  
to P-gp expression. 
2. Materials and Method 
2.1. Collection of Samples 
This is an observational study with cross sectional methods.  Study was conducted within a population of breast 
cancer patients who had been diagnosed through clinical and histopathology examination, which entered the 
Wahidin Sudiro Husodo Hospital in Makassar, South Sulawesi, Indonesia, starting from July 2015 to September 
2016.  Inclusion criteria are locally advanced breast cancer female patient and invasive ductal breast cancer.  
Exclusion criteria were inadequate tissue samples for immunohistochemistry and bilateral breast cancer. All 
samples who fulfilled inclusion and exclusion criteria and willing to participate in the study and signing 
informed consent recruited as study samples.  
2.2. Laboratory Procedures 
Acquired samples from incisional biopsy of breast cancer patients treated in Wahidin Sudirohusodo hospital for 
paraffin block and immunohistochemistry examination of Estrogen Receptors and P-gp.  Each paraffin block 
was cut with a microtome size of 4 microns and placed on an object glass. Immunohistochemistry staining using 
standard techniques. From each paraffin blocks, subject were stained with hematoxylin eosin for 
histopathological examination, and staining for estrogen receptors and P-gp. Subject then examined to determine 
the type of cancer and  determination ER and P-gp expression. 
2.3.  Immunohistochemistry Interpretation 
Expresion of  ER and P-gp is the accumulation of proteins in the membrane and cytoplasms of cells, detected by 
Immunohistochemistry methods were then expressed positive when using a light microscope, it would look 
brown on the location of the antigen to be detected. This expression is calculated using a scoring system based 
on the intensity of color and proportion of epithelial cells stained. 
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2.4. Data Analysis 
Data analysis using the SPSS (Statistical Package for Social Science) version 22. Chi square analysis were used 
to assess the relationship of ER and P-gp expression. 
2.5. Ethical Clearence 
Ethical approval for this study was obtained from Research Ethics Committee, Faculty of Medicine, Hasanuddin 
University, Makassar, Indonesia. Number; 581/H4.8.4.5.31/PP36-KOMETIK/2015. 
3. Results 
We recruited 55 patients of invasive ductal carcinoma during July 2015 to September 2016, originated from 
Wahidin Sudirohusodo Hospital.  
 
 
Figure 1: Microphotographs of ER immunostaining in 
invasive ductal carcinoma.  Positive Results in 400 x 
Figure2: Microphotographsof Pgp 
immunostaining in invasive ductal carcinoma.  
Positive Results in 400 x 
Table 1: Characteristics of Samples 
Characteristics  N % 
Age 
 
< 50 33 60 
≥ 50  22 40 
Grading 
  
             
Low 
Moderate 
High 
9 
32 
14 
16 
58 
26 
ER expression Positive 35 63.6 
Negative 20 36.4 
PR  expression Positive 24 44 
Negative 31 56 
HER  expression Positive 19 35 
Negative 36 65 
P-gp  expression Positive 10 18.2 
Negative 45 91. 
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Youngest age of subject was 29 years and the oldest was 75 years old,  60% in the age group < 50 years.  Low 
grade 9(16%), Moderate grade 32(58%) and in High grade 26(26%). Results of immunohistochemistry 
examination; ER+ showed in 35 (63.6%)  samples, PR + in 24 (44%), HER2 + in 19(35%) while P-gp (+) as 
much as 10 (18.2%) samples.  
Table 2: Relationship of ER expression and PgP expression 
ER expression 
P-gp Expression 
Total 
Positive  (%) Negative (%) 
Positive 6 (17.1) 29(82,9) 35 (100) 
Negative 4(20) 16(80) 20(100) 
Total 10(37.1) 45(62.9) 55(100) 
p value=0.076 (p>0.05), OR(95%CI) 1.2(0.21-5.99) 
 
In chi square analysis,  there is no significant relationship between ER and Pgp expression with p = 0.076 
(p>0.05).  It means that ER expression is less associated with Pgp expression in invasive ductal carcinoma. 
4. Discussion 
Studies revealed that drug-resistant influenced by Multidrug Resistance gene 1 (MDR1) in association with 
over-expression of P-gp, which is a member of the ATP-binding cassette (ABC) transporter which serves as 
pumps out a variety of chemotherapy agents such as anthracyclines and taxanes [6].  The expression of P-gp 
encoded by the gene Multidrug-resistant (MDR) located at kromosum 7q2.1.1 7q2.1.1 [7],  comprises 28 exons 
that encode a protein of 1280 amino acids containing two ATP-biding site and two transmembrane domains that 
work as energy dependent pump, P-gp is actively pumping out a particular group of cells chemotherapeutic 
agents [8,9]. comprises 28 exons that encode a protein of 1280 amino acids containing two ATP-biding site and 
two transmembrane domains that work as energy dependent pump, P-gp is actively pumping out a particular 
group of cells chemotherapeutic agents[10].  While other studies have shown a positive expression of P-
glycoprotein prior chemotherapy by 52% [11].  Some P-gp expression research report that the percentage of P-
gp expression increased post chemotherapy [12,13].  
This study found the proportion of positive expression of P-gp by 6 (17.1%) in invasive ductal breast carcinoma 
expressing ER (+) 35 samples. This indicates that ER + contribute to the expression of P-gp. 
Relations ER and P-gp / MDR1 proven through many research,  ER activates transcription of MDR1 in MCF-7 
breast cancer cells by binding to ERE 1/2 and interacting with AP-1 element CG-Rich in MDR1 promoter [15, 
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16].  The transcription factor AP-1 has been identified in the promoter region of the gene MDR1 [17, 18].  ER 
involvement on the expression of P-gp may also through the activation of signaling pathways PI3K / AKT 
indicating convergent point, the deviation of this pathway led to increased expression of P-gp / MDR1 and 
resistance to chemotherapy [19]. Similarly, activation of MAPK / ERK significantly increased the expression of 
P-gp / MDR1 (Tomiyasu and his colleagues 2013).  In addition, non-genomic pathways may also be activated 
by a heat shock protein, Platelet-derived growth factor (FDGF) and Epidermal growth factor (EGF) [20]. 
Similarly, the expression of P-gp in breast carcinoma with expression of ER (-) indicates that the expression of 
P-gp not only depend on the ER (+), but the expression of P-gp also affected by overexpression of signal 
cascades such as stimulation factor of epidermal growth (EGF ), overexpression of HRAS, c-Raf, MEK1 / 2, 
ERK1 / 2 also increased expression of P-gp [21].  
P-gp expression in this study may reflect the MDR1 gene expression as an intrinsic resistance in invasive ductal 
carcinoma of the breast. MDR intrinsic (primary) mediated by overexpression of MDR1 / P-gp was MDR 
acquired (secondary) induced by a variety of cytotoxic agents, UV radasi, heat shock [22,23]. 
The limitations of this study were; Neoadjuvant chemotherapy is only done three cycles, which aims to 
downsizing until the tumor becomes resectable, so that in this study no cases were found to achieve pCR 
(pathological complete response). Measurement of dependent variable were using the manual method by using a 
caliper. 
5. Conclusion 
Results of this study suggest that ER does not play a signiﬁcant role in the expression of P-gp in invasive ductal 
carcinoma of  breast cancer.  Based on this study, it can be suggested for further study of P-gp expression in 
breast cancer. 
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